High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.

[1]  M. Gilbert,et al.  MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials , 2018, Clinical Cancer Research.

[2]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[3]  Leiming Wang,et al.  Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. , 2017, Pathology, research and practice.

[4]  R. Fimmers,et al.  ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial , 2017 .

[5]  N. Lindeman,et al.  The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. , 2016, The Journal of molecular diagnostics : JMD.

[6]  F. Ducray,et al.  Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial , 2016, Oncotarget.

[7]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[8]  C. Sommer,et al.  MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response , 2016, Clinical Epigenetics.

[9]  Mauro Delorenzi,et al.  Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. , 2016, The Journal of molecular diagnostics : JMD.

[10]  A. Saâd,et al.  MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry , 2016, Clinical and Translational Oncology.

[11]  D. Amadori,et al.  Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma , 2016, Journal of Neuro-Oncology.

[12]  H. Heinzl,et al.  Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions , 2015, Clinical neuropathology.

[13]  Anne K. Braczynski,et al.  Confounding Factors in Diagnostics of MGMT Promoter Methylation Status in Glioblastomas in Stereotactic Biopsies , 2014, Stereotactic and Functional Neurosurgery.

[14]  M. Sanson,et al.  Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients , 2014, Journal of Neuro-Oncology.

[15]  M. Delorenzi,et al.  MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.

[16]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[17]  H. Zentgraf,et al.  Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.

[18]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[19]  Ivo G Gut,et al.  DNA methylation analysis by pyrosequencing , 2007, Nature Protocols.

[20]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[21]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[22]  A. Dullea,et al.  MGMT testing allows for personalised therapy in the temozolomide era , 2015, Tumor Biology.